Amneal Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Amneal Pharmaceuticals achieved significant revenue growth in 2025, driven by new product launches and biosimilar approvals, despite ongoing competitive and regulatory challenges.
NASDAQ
Amneal Pharmaceuticals' 2024 10-K filing reveals a year of mixed financial performance, marked by strategic collaborations and a significant opioid litigation settlement.
NASDAQ
Amneal Pharmaceuticals' 2023 10-K filing provides a comprehensive overview of its capital stock, business segments, financial performance, and risk factors, highlighting a year of strategic reorganization and operational expansion.